Drug Trial Radar · NCT00557440
Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma
Last checked: Nov 19, 2026Latest source record: Mar 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Nov 2007
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 14, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to provide data about the 24 hours FEV1 profile, safety and tolerability of indacaterol/mometasone TWISTHALER device compared to placebo and using fluticasone/salmeterol as an active control.
Conditions
- Asthma
Interventions
fluticasone propionate/salmeterolDrug
Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
indacaterol maleate / mometasone furoateDrug
Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
placebo to indacaterol/mometasoneDrug
Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
placebo to fluticasone propionate/salmeterolDrug
Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)Time frame: Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16).
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigator Site
Aalst, Belgium
Novartis Investigator site
Ghent, Belgium
Novartis Investigator Site
Berlin, Germany
Novartis Investigator Site
Hanover, Germany
Novartis Investigator Site
Landsberg, Germany
Novartis Investigator Site
Rostock, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.